Key result
CYP2C19*2 status associated with ~33% higher platelet reactivity versus wild-type in CAD patients on clopidogrel.
Why the study?
The influence of CYP 2C19*2 polymorphism on platelet inhibition during clopidogrel treatment in symptomatic coronary artery disease patients was unclear.
Does the CYP 2C19*2 polymorphism increase platelet reactivity and clopidogrel resistance in patients with stable CAD on single antiplatelet treatment with clopidogrel?
Observational (n=219)
Open-label
No
Does the CYP 2C19*2 polymorphism increase platelet reactivity and clopidogrel resistance in patients with stable CAD on single antiplatelet treatment with clopidogrel?
Patients with stable CAD on single clopidogrel therapy carrying the CYP 2C19*2 polymorphism exhibit significantly higher platelet reactivity and clopidogrel resistance compared to wild-type patients.
Answers are grounded in this paper and cite their sources.
CYP2C19*2 may identify reduced clopidogrel response in CAD; leaves open whether genotyping improves outcomes.
BACKGROUND: Different platelet function tests can be used to evaluate the degree of achieved platelet inhibition in patients treated with clopidogrel. The presence of CYP 2C19*2 polymorphism can reduce the formation of the active metabolite of clopidogrel, resulting in less platelet inhibition. PATIENTS AND METHODS: Patients with symptomatic coronary artery disease, all on chronic single aspirin treatment were randomized to continue on aspirin or change to clopidogrel. In 219 randomly selected clopidogrel treated patients, platelet reactivity was evaluated by VASP-PRI determination and by use of VerifyNow P2Y12-PRU. The CYP 2C19*2 G/A polymorphism was further determined. RESULTS: The total frequency of clopidogrel resistance was 29.0% by VASP-PRI and 31.6% by VerifyNow-PRU. The number of patients being hetero- and homozygous combined for the CYP 2C19*2 polymorphism (GA/AA) was 64 (29%). Platelet reactivity was significantly higher in patients with the polymorphism compared to wild-type patients (GG). VASP-PRI was 50.9% (SD19) in patients having the polymorphism compared to 38.3% (SD21) in patients with the GG genotype (p = 0.001). Correspondingly, the mean PRU was 165 (SD67) compared to 124 (SD69) (p < 0.001). The frequency of clopidogrel resistance in patients with the polymorphism was 32% compared to 16% in wild-type patients when defined by VASP-PRI (p = 0.006). When defined by PRU (VerifyNow), the corresponding frequencies were 53% and 22% (p < 0.001). CONCLUSIONS: Clopidogrel treated patients with the CYP 2C19*2 polymorphism have significantly increased platelet reactivity compared to patients with the wild-type, evaluated with the VASP determination, and even more pronounced with the VerifyNow P2Y12 method. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00222261.
No takes yet. Share an insight, caveat, or question.
Pettersen et al. (2011) conducted an observational in Stable symptomatic coronary artery disease (n=219). CYP 2C19*2 polymorphism (GA/AA) vs. Wild-type (GG) was evaluated on Platelet reactivity measured by VASP-PRI (p=0.001). Patients with stable coronary artery disease on single clopidogrel treatment carrying the CYP2C19*2 polymorphism had higher platelet reactivity compared to wild-type patients.
Synapse has enriched 10 related papers. Consider them for comparative context: